| Title: | Identification of a plasma proteomic signature associated with sudden cardiac death risk in the UK biobank |
| Journal: | Frontiers in Cardiovascular Medicine |
| Published: | 8 May 2026 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/42181647/ |
| DOI: | https://doi.org/10.3389/fcvm.2026.1831086 |
Publication 20118
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Background: Sudden cardiac death (SCD) remains difficult to predict in the general population, and proteomics may offer additional prognostic information. We aimed to develop and evaluate a plasma proteomic signature for SCD risk prediction in the UK Biobank.</p>
Methods: We analyzed prospective data from 52,826 UK Biobank participants, including 408 incident SCD cases. A proteomic signature was derived using repeated LASSO-Cox regression. Its biological relevance was explored by GO enrichment and PPI analyses. Predictive performance was assessed by discrimination, reclassification, calibration, and decision curve analysis.</p>
Results: A 71-protein signature was identified. Each 1-SD increase in the proteomic signature was associated with a higher risk of incident SCD (HR 3.25, 95% CI 2.94-3.58). Although non-proportional hazards were detected, the time-dependent association remained positive throughout follow-up. The proteomic-signature model showed substantially better discrimination than the clinical model (AUC 0.871 vs. 0.770), whereas the combined model provided only minimal additional improvement (AUC 0.872). Compared with the clinical model alone, the combined model improved reclassification (IDI 0.033, 95% CI 0.022-0.050; continuous NRI 0.403, 95% CI 0.351-0.459; both p < 0.001). Calibration was good, and net clinical benefit was mainly observed at relatively low threshold probabilities. Sensitivity analyses supported the robustness of the findings.</p>
Conclusion: The proteomic signature was independently associated with incident SCD and improved risk stratification beyond the clinical model. However, its clinical utility should be interpreted cautiously, and external validation is required before clinical application.</p>
11 Authors
- Sijia Dai
- Minjia Wu
- Lei Zheng
- Yuyu Chen
- Shaoni Huang
- Jiangyan Hao
- Feiling Liu
- Xiaowei He
- Guangfeng Long
- Yunfeng Zou
- Cheng Xu
1 Application
| Application ID | Title |
|---|---|
| 140851 | The impact of social factors, lifestyle, psychological status, environmental factors, and genetic factors on the occurrence, progression, and mortality risk of chronic noncommunicable diseases |
Enabling scientific discoveries that improve human health